Gut mucosal macrophages play a pivotal role in driving mucosal immune responses, resulting in either activation of inflammatory immune responses to pathogenic challenge or tolerance to beneficial luminal contents such as food and commensal bacteria. Macrophage responses elicited are dependent on tissue environment and the resulting cell subset, where homeostatic macrophages resemble the M2 macrophage subset and inflammatory macrophages resemble M1s. Probiotics can modulate macrophage function with outcome dependent on subset present. Using a THP-1 monocyte cell line-derived model of CD14 high/low M1 and M2 macrophages, the aim of this study was to investigate the immunomodulatory effects of a panel of heat-killed probiotic bacteria and their secreted proteins on the subset-specific inflammatory marker profile of TNFα, IL-6 and NFκB. M1 and M2 cells were generated by differentiation of monocyte stable transfectants for high and low CD14 expression with phorbol 12-myristate 13-acetate and vitamin D 3 , respectively, where the resulting CD14 lo M2 and CD14 hi M1s mimicked homeostatic and inflammatory mucosal macrophages. Subsets were stimulated by enteropathic lipopolysaccharides in the presence or absence of heat-killed (HK) or secreted proteins (SP) from a panel of probiotic bacteria. Regulation of cytokine expression was measured by ELISA and NFκB activity by reporter assay. HK probiotics suppress CD14 lo and augment CD14 hi M1 and M2 production of TNFα whereas SPs augmented CD14 hi M1 TNFα and were generally suppressive in the other subtypes. M2 macrophage IL-6 production was suppressed by both HK and SPs and differentially regulated in CD14 lo and CD14 hi M1s. NFκB activation failed to parallel the regulatory profiles for TNFα and IL-6 which is suggestive of probiotic bacteria exerting their regulatory effects on these cytokines in an NFκB-independent manner. In conclusion, HK and SP probiotics differentially regulate macrophage cytokines and NFκB activation in a subset-dependent manner and suggest a cautionary approach to probiotic treatment of mucosal inflammation.
1.Introduction
The gut mucosal immune system is a major site of defence against potential pathogenic organisms that gain entry into the human body via the gastrointestinal tract (GIT). By its very nature, the GIT is full of microbes, their antigens and potential antigens released by the chemical breakdown of food. The mucosal immune system of the gut, in response to this microbe and food-antigen-rich environment has developed sophisticated mechanisms by which it can selectively taste luminal contents and respond to these signals; either by initiation of an immune inflammatory response or by a homeostatic mechanism resulting in tolerance or non-responsiveness of the immune system, whereby we tolerate useful products in the gut. This mechanism is referred to as oral tolerance, allowing the host to gain benefit from food/nutrients and beneficial commensal organisms.
These commensal microbes present in the gut afford health benefits through a variety of ways which include provision of metabolites which regulate host nutrition, epithelial School of Biomedical and Biological Sciences, University of Plymouth, Drake Circus, Plymouth PL4 8AA, United Kingdom; andrew.foey@plymouth.ac.uk cell turnover and compete with pathogenic organisms for nutrient sources and binding sites on epithelial cells, thus preventing pathogenic invasion/infection. More recently, these organisms have been observed to modulate gut mucosal immune function which has been the focus of much intense investigation. In addition, the 'topping-up' of these 'friendly' bacteria by probiotics has been established to modulate immune function and confer health benefit to allergies, inflammatory pathologies and cancer.
Integral to modulation of gut mucosal responses are the macrophage cells present in the lamina propria of the mucosal layer. Gut mucosal macrophages are generally hyporesponsive or tolerised in the homeostatic healthy functioning gut: hyporesponsive to nutrients, food antigens and commensals whereas retaining the ability to be activated and elicit an inflammatory immune response upon pathogenic challenge. These macrophages are generally representative of the M2 macrophage subset, they express scavenger receptors (mannose receptor MR, CD13, CD36), anti-inflammatory/regulatory cytokines (interleukin (IL)-10 and transforming growth factor, TGFβ) and exhibit a reduced responsiveness to pathogen associated molecular patterns (PAMPs), i.e. macrophages fail to express CD14 and selected Toll-like receptors (TLRs); but in addition, the expression of the co-stimulatory molecules CD80/CD86 and the IgA FcR, CD89 are also reduced. These CD14 lo M2-like macrophages, when in homeostatic conditions, are predominantly regulatory/anti-inflammatory and display a phagocytic phenotype characterised by the high expression of scavenger receptors (Platt and Mowat, 2008; Smith et al., 2001; Smythies et al., 2005) . Macrophage effector phenotype, however, is partially governed by the local environment. Thus, in an inflammatory environment, gut mucosal macrophages exhibit a pro-inflammatory M1-like macrophage subset effector phanotype, characterised by the predominance of pro-inflammatory cytokine production, expression of high levels of CD14 (CD14 hi ) and expression of co-stimulatory molecules CD80 and CD86 (Segura et al., 2002; Zareie et al., 2001) . It is not clear, however, whether these different macrophage effector phenotypes result as a consequence of plasticity of one subset of gut macrophage cell or by recruitment and activation of a defined monocyte/ macrophage subset from the peripheral circulation.
Probiotic bacteria are immunomodulatory and can exert their effects on a wide array of immune and mucosal cells including T-cells, B-cells, natural killer (NK) cells (Takeda et al., 2006) , dendritic cells (Foligne et al., 2007a) , monocytes/macrophages and epithelial cells (Zhang et al., 2005) . Dependent on cell type and strain of probiotic bacteria used, these immunomodulatory effects can manifest themselves as immune activatory, deviatory or regulatory/suppressive. Considering relative abundance and functionality in the gut mucosa, the potential role of probiotics in modulating macrophage function has been relatively sparsely investigated. Lactic acid bacteria (LAB), such as Lactobacillus rhamnosus, have been documented to modulate macrophage function by both suppressing and enhancing IL-12 production (Foligne et al., 2007b; Ichikawa et al., 2007; Shida et al., 2006) , which will impact on Th 1 development and activation, hence cell mediated immunity to intracellular resident pathogens. These LAB have also been described to suppress mucosal tumour necrosis factor (TNFα) during inflammation (Borruel et al., 2002) and to augment the anti-inflammatory cytokine, IL-10 (Foligne et al., 2007b) . In addition, the secreted protein extract from Lactobacillus plantarum inhibits NFκB activity (Petrof et al., 2009 ); such observations have suggested a suppressive role for L. plantarum and other probiotic bacterial species on NFκB-dependent inflammatory cytokines such as IL-1γ, IL-6, IL-8, monocyte chemotactic peptide-1 (MCP-1), IL-12 and TNFα. Thus, probiotic bacteria have been demonstrated to exert their immunomodulatory effects through both bacterial cell-associated mechanisms and through soluble secreted proteins (Frick et al., 2007; Sanchez et al., 2009; Yan et al., 2007) and metabolites such as short chain fatty acids (Foey, 2011) .
These probiotic bacteria share common molecules (or pathogen associated molecular patterns, PAMPs) with pathogenic bacteria, which are recognised by pattern recognition receptors (PRRs) expressed by cells of the gut mucosa. Just how the immune system recognises beneficial commensal or probiotic microbes from pathogens is a subject of intense research efforts. One potential way by which the host differentiates between good and bad has been suggested to be mediated by the PRR, nucleotide oligomerisation domain-2 (NOD2); indeed several probiotic LAB strains have been shown to be recognised by this receptor (Hasegawa et al., 2006) . NOD2 is an intracellular receptor which recognises muramyl dipeptide moieties derived from peptidoglycan (Girardin et al., 2003) ; the location of this receptor suggests that either the whole probiotic bacterium or parts of, are required to gain entry inside the cell by means of phagocytosis. This in itself, is suggestive of phagocytically competent cells such as the M2 macrophage subset and the potential role of scavenger receptors which predominate on the same cell type. Such a mechanism may be important in macrophage discrimination between commensals and pathogens, preventing inappropriate recognition of commensal PAMPs by their PRRs and the ensuing destructive inflammatory immune responses; thus mediating tolerance vs. immune activation decisions. Indeed, probiotic bacteria have been demonstrated to modulate phagocytosis; whereby being stimulatory to phagocytosis in healthy subjects and conversely, suppressive in allergic patients (Isolauri et al., 2001) . Thus, recognition of PAMPs by PRRs such as TLRs and NODs, the phagocytic capability and functional phenotype of the macrophage determine responsiveness to probiotics as immuno-suppressive, regulatory or inflammatory.
Gut mucosal macrophages have been characterised as CD14 lo/absent , TLR lo/absent M2-like phenotype in healthy mucosa whereas CD14 hi , TLR hi M1-like phenotype in inflammatory mucosa (Smith et al., 2001; Smythies et al., 2005; Zareie et al., 2001) . Thus, CD14 has been suggested as an indicator molecule of tolerogenic or inflammatory mucosal macrophages. CD14 is a multifunctional receptor; it facilitates innate responses to infectious non-self molecules as well as interacting with apoptotic self molecules, serving as a scavenger for apoptotic cells. It has been described to recognise the bacterial PAMPs; lipopolysaccharide (LPS), peptidoglycan, mycobacterial lipoarabinomannan and streptococcal cell wall polysaccharides (Pugin et al., 1994; Soell et al., 1995; Weidemann et al., 1997; Wright et al., 1990) , thus having the capability to recognise and bind components of both Gram negative and Gram positive bacteria and serving as a co-receptor for TLR2 and TLR4, hence driving inflammatory immune responses directed at non-self bacterial components. On the other hand however, CD14 has been demonstrated to recognise apoptotic cells for clearance by phagocytosis (Devitt et al., 1998; Pradhan et al., 1997) . Such a clearance mechanism results in a regulatory, anti-inflammatory response (Fadok et al., 1998) . Probiotic modulation of these functionally distinct macrophage subsets present in the gut mucosa will be determined by CD14 expression and the receptors that it associates with, and the downstream effector signalling pathways.
The signal pathway transcription factor, NFκB plays a dominant role in inflammatory responses. It has been well established to regulate macrophage inflammatory cytokine production such as TNFα, IL-6, IL-8 and IL-1β (Bondeson et al., 1999) . In addition, the role of NFκB in regulating macrophage phenotype has been investigated where inhibition of NFκB by adenovirus overexpression of the inhibitor, IκB, changed macrophage phenotype to a dominant anti-inflammatory phenotype (Wilson et al., 2005) . This was extended, whereby an anti-inflammatory role was described for IKKβ by the inhibition of classical, M1-like macrophage responses (Fong et al., 2008) . Surprisingly, the long term inhibition of IKKβ rendered mice more susceptible to IL-1β-associated endotoxin-induced shock. Inhibition of IKKβ, hence NFκB activation and NFκB-dependent inhibition of caspase-1 resulted in augmentation of IL-1β, demonstrating NFκB to play a negative regulatory role in IL-1β secretion (Greten et al., 2007) . Thus, it is likely that macrophage phenotype, hence inflammatory phenotype, is integrally associated with NFκB subunit association and activation. Several studies have suggested that probiotics (both bacterial cell-associated and bacterial-free fractions) modulate NFκB activation, whereby VSL#3 suppressed NFκB activation in intestinal epithelial cells (Petrof et al., 2004 (Petrof et al., , 2009 ) and the same cells in a murine model of colitis (Marteau et al., 2004) . It remains to be investigated whether probiotic modulation of distinct macrophage subsets and their effector cytokines is mediated through manipulation of NFκB-dependent mechanisms.
Current understanding of probiotic modulation of macrophage-mediated immune responses of distinct effector subsets relevant to mucosal homeostatic and inflammatory pathological environments is relatively poorly understood. Probiotic modulation of macrophage effector cytokines is, at best, confusing and often contradictory; observations being determined by cell source, level of differentiation, bacterial strain, bacterial preparation, stimulus used and local environment. Using a stably transfected NFκB-reporter cell line model of CD14 lo / CD14 hi mucosal resident homeostatic-and infiltrating inflammatory-macrophages, the aim of this study was to investigate the relationship between a range of potentially immunoregulatory panel of probiotics (both bacterial cell and secreted protein preparations) and their effects on macrophage subset NFκB activation and corresponding cytokine effector phenotype, of relevance to mucosal macrophages found in the gastrointestinal tract.
Materials and methods

Bacterial culture and preparation of heat-killed and secreted protein extracts
Bifidobacterium breve strain NCIMB 8807 (BB), L. rhamnosus GG strain NCIMB 8824 (LR), Lactobacillus salivarius strain NCIMB 41606 (LS) and L. plantarum strain NCIMB 41605 (LP) were obtained from NCIMB (Aberdeen, UK). Lactobacillus fermentum strain MS15 (LF) was isolated from the crop of a chicken (Savvidou, 2009 ) and obtained from internal microbiology stocks at the University of Plymouth (UK). These probiotic bacterial species were cultured aerobically in De Man Rogosa Sharp (MRS) broth at 37 °C for 18 hours until stationary phase was achieved. Bacterial cells were harvested according to the method described in Habil et al. (2011) . In brief, bacterial cells were harvested and washed in phosphate buffered saline and viable counts adjusted to a density of 1×10 9 cfu/ml. Probiotic bacteria were adjusted to 1×10 10 cfu/ml and heat killed for 2 hours at 90 °C (HK) according to the protocol of Young et al. (2004) . Cell death was confirmed by plating on MRS agar and incubation for a minimum of 18 hours. In addition, secreted protein (SP) was extracted by trichloroacetic acid precipitation of proteins secreted into growth supernatant according to the protocol of Sanchez et al. (2009) . Protein content was verified by SDS-PAGE and quantified by calibration to Bradford protein assay. Secreted protein was adjusted to a stock concentration of 1 mg/ml.
Monocyte and macrophage culture
Transfectant human monocytic THP-1 NFκB reporter cell lines, THP-1Blue (CD14 lo ) and THP-1Blue-CD14 (CD14 hi ) (Autogen Bioclear, Calne, UK) were routinely used for this study between passages 7 and 25 and maintained in R10 medium composed of RPMI-1640 medium supplemented with 10% (v/v) foetal calf serum, 2 mM L-glutamine and 100 U/ml penicillin or 100 μg/ml streptomycin (Lonza, Wokingham, UK) in the presence of the selection antibiotics, 200 μg/ml zeocin or 200 μg/ml zeocin and 10 μg/ml blastocidin, respectively. Cells were plated out at 1×10 5 cells/100 μl/well in R10 medium in 96 flat-bottomed well tissue culture plates. Pro-inflammatory (M1-like) macrophages and anti-inflammatory (M2-like) macrophages were generated by differentiation of these monocytes in the presence of 25 ng/ml phorbol 12-myristate 13-acetate for 3 days or 10 nM 1,25-(OH) 2 -vitamin D 3 (Sigma-Aldrich, Poole, UK), for 7 days, respectively (Daignealt et al., 2010) . The resulting CD14 lo M2 and CD14 hi M1 macrophage subsets were representative of homeostatic and inflammatory pathological mucosal macrophages, respectively. In addition, CD14 lo M1 and CD14 hi M2 subsets were also studied, acting as internal controls for observations of CD14 expression responses of the inflammatory pathological and homeostatic macrophages, and as potential intermediate subsets dependent on whether the macrophage subset is derived from recruited CD14 hi /CD14 lo peripheral blood monocytes or as a consequence of environmental modification of resident mucosal macrophages.
Activation of macrophage cytokine production
Macrophages were stimulated by the bacterial PAMP; 100 ng/ml Escherichia coli strain K12 LPS (expressed in enteropathic Gram negative bacteria and detected by TLR4) and cultured for 18 hours (determined as optimal time period for secretion of the cytokines TNFα and IL-6) in a humidified environment at 37 °C, 5% CO 2 , after which time supernatants were harvested and stored at -20 °C until required for assay by sandwich ELISA.
Regulatory effect of heat-killed and secreted protein probiotic preparations
To investigate probiotic regulation of macrophage cytokine production and NFκB activation, HK-and SP-probiotics were added in culture to final concentrations of 3×10 8 bacterial cells/ml and 3 μg/ml, respectively, as a pretreatment for 18 hours prior to K12-LPS stimulation (100 ng/ml) for a further 18 hours in a humidified environment at 37 °C, 5% CO 2 . To demonstrate a physiologically-relevant role for HK-and SP-probiotics, cytotoxicity assays (MTT and trypan blue exclusion) were carried out on both macrophages, up to 10 9 cells/ml and 100 μg/ml, respectively. No significant reductions in viability were observed for the concentrations used; viability was routinely >90%.
Cytokine measurement
Macrophage production of the inflammatory cytokines, TNFα and IL-6, were analysed by sandwich ELISA using commercially available capture and detection antibodies from BD-Pharmingen (Oxford, UK). Due to supernatant volume constraints, the CD14 hi and CD14 lo NFκB reporter transfectants were assayed for the pro-inflammatory cytokine, TNFα, and the dual pro-and anti-inflammatory cytokine, IL-6, and NFκB activity (see next paragraph). Protocols were followed according to manufacturer's instructions and compared to standard curves, using the recognised international standards available from NIBSC (Potter's Bar, UK). Colorimetric development was measured spectrophotometrically by an OPTIMax tuneable microplate reader at 450 nm and analysed by Softmax Pro version 2.4.1 software (Molecular Devices Corp., Sunnyvale, CA, USA).
NFκB activity measurement
NFκB activity was measured by colorimetric reporter gene assay for secreted embryonic alkaline phosphatise (SEAP) associated with the stably-transfected reporter gene cell lines, THP-1Blue (CD14 lo ) and THP-1Blue-CD14 (CD14 hi ) (Autogen Bioclear). Briefly, at conclusion of the experiment, fresh supernatant was harvested and incubated with Quantiblue colorimetric reagent (Autogen Bioclear) for 30 minutes at 37 °C, 5% CO 2 . Colorimetric development was measured by an OPTIMax tuneable microplate reader at 620 nm and analysed by Softmax Pro version 2.4.1 software (Molecular Devices Corp.). Colour development was directly proportional to the reporter gene SEAP expression and NFκB activity.
Statistical analysis
Data were analysed using balanced analysis of variance (General Linear Model, Minitab version 16) followed by a multiple comparison test (LSD, least significant difference test). All means are presented with the appropriate standard error. Significance was set at the confidence intervals of 0.05, 0.01 and 0.005.
Results
Secreted protein and heat-killed probiotic strains selectively modulate macrophage subset TNFα production Mucosal macrophage effector phenotype and functions differ from other tissue macrophages. They are generally hyporesponsive CD14 lo when present in homeostatic, tolerogenic mucosa whereas under inflammatory conditions they are CD14 hi and express inflammatory mediators. In an attempt to extrapolate earlier data to gut mucosal macrophages in inflammatory or tolerogenic conditions, CD14 hi and CD14 lo stable transfectants were driven towards M1 and M2 macrophage subsets and stimulated by K12-LPS in the presence or absence of heat-killed or secreted protein preparations from a range of probiotic bacterial species.
Probiotic bacteria have been demonstrated to modulate innate immunity. This experiment was undertaken to establish whether heat-killed (in the absence of any nonspecific effects of lactic acid produced) or secreted protein from a panel of established probiotic bacteria exerted immunomodulatory effects on the expression of the proinflammatory cytokine, TNFα, by THP-1-derived M1-like and M2-like macrophage subsets. Results indicated that HK-and SP-probiotic bacteria samples differentially regulated LPS-induced TNFα production by M1 and M2 macrophage subsets; modulation of TNFα being dependent on macrophage subset, CD14 expression and probiotic strain. The most obvious effect was observed for CD14 hi macrophages, where in CD14 hi M1s (representative of inflammatory infiltrating macrophages) heat killed probiotics augmented LPS-induced TNFα by ×4, ×3.2, ×3.6, ×4 and ×3.7 of control (1,161±148 pg/ml) and secreted proteins augmented by ×4, ×4.1, ×4.1, ×3 and ×3.5 for BB, LR, LF, LS and LP, respectively ( Figure 1B ). CD14 hi M2s displayed a differential sensitivity to HK compared to SP ( Figure 1D ). HK obtained for the LABs all augmented TNFα production (control 14±1 pg/ml) resulting in levels ×4.9, ×12, ×3.6 and ×7 for LR, LF, LS and LP, respectively. SP extracts, in comparison, only weakly modulated cytokine production where LS suppressed production by 36% (control 14±1 pg/ml to 9±1 pg/ml) and LP augmented by 86% (control 14±1 pg/ml to 26±3 pg/ml). Generally, in the case of CD14 lo macrophages, HK and SP probiotics partially suppressed LPS-induced TNFα production. In the case of CD14 lo M1s, HK suppressed cytokine production (control levels of 1,454±94 pg/ml) by 51% (709±4 pg/ml), 19% (1,184±98 pg/ml), 40% (876±175 pg/ml) and 57% (628±316 pg/ml) for BB, LF, LS and LP, respectively. SP suppressed by 47% (770±120 pg/ml), 59% (590± 6 pg/ml) and 52% (704±119 pg/ml) for LR, LF and LP. ( Figure 1A ). Finally, in the case of CD14 lo M2 macrophages (representative of homeostatic healthy gut mucosal macrophages), HK suppressed TNFα (control 21±2 pg/ml) by 62%, 38%, 33%, 57% and 52% for BB, LR, LF, LS and LP. SP suppressed by 19%, 62%, 24% and 67% for BB, LF, LS and LP, respectively, whereas LR-SP augmented TNFα by 38% ( Figure 1C ).
Secreted protein and heat-killed probiotic strains selectively modulate macrophage subset IL-6 production
The data above clearly demonstrates an immunomodulatory role for both HK and SP probiotics with respect to the expression of the pro-inflammatory cytokine TNFα by pro-inflammatory (M1) and anti-inflammatory/regulatory (M2) macrophage subsets. These macrophage subsets have been described to express different cytokine profiles which underlie their effector function; one such differential cytokine which exhibits both pro-inflammatory and antiinflammatory properties is IL-6. This experiment was undertaken to establish whether HK and SP probiotics exerted any selective immunomodulatory effects on the expression of IL-6 by M1 and M2 macrophage subsets. Results indicated that HK and SP differentially regulated IL-6 cytokine expression by M1 and M2 macrophage subsets. Both HK and SP preparations suppressed LPSinduced IL-6 production by M2 macrophages, potency of suppression being regulated by the level of CD14 expression. With respect to CD14 lo M2 macrophages (representative of homeostatic healthy gut mucosal macrophages), HK suppressed IL-6 (control 547±52 pg/ml) by 58%, 58%, 34%, 98% and 91% for BB, LR, LF, LS and LP. SP suppressed by 86%, 19%, 73%, 94% and 92% for BB, LR, LF, LS and LP, respectively ( Figure 2C ). IL-6 production by CD14 hi M2s was highly sensitive to suppression, where HK suppressed cytokine production (control 1,681±144 pg/ml) by 98%, 96%, 95%, 99% and IL-6 (pg/ml) IL-6 (pg/ml) IL-6 (pg/ml) 98% and SP suppressed by 95%, 95%, 93%, 96% and 95% for BB, LR, LF, LS and LP, respectively ( Figure 2D ). Proinflammatory M1 macrophages exhibit a different IL-6 regulatory profile upon exposure to HK and SP probiotics. CD14 lo M1 macrophages HK-BB, HK-LR, HK-LS and HK-LP augment LPS-induced IL-6 (control 216±5 pg/ml) by ×1.3, ×2.6, ×1.8 and ×2.1, respectively, whereas HK-LF suppressed IL-6 production by 29% (Figure 2A) . LR-SP, LS-SP and LP-SP suppressed IL-6 by 30%, 26% and 49%, LF-SP augmented cytokine production by ×1.4 and BB-SP failed to modulate LPS-induced IL-6 (Figure 2A ). The CD14 hi M1 subset (representative of infiltrating inflammatory mucosal macrophages) displayed an intriguing profile upon introduction of heat-killed or secreted protein of these probiotic strains. Heat-killed LF, LS and LP suppressed IL-6 (LPS control 62±8 pg/ml) by 61%, 61% and 74%, whereas the secreted protein from the same strains augmented production by 55%, 26% and 11%, respectively. HK-LR. and LR-SP suppressed IL-6 by 17% and 11%. Finally, B.
breve failed to modulate LPS-induced IL-6 in these proinflammatory macrophages ( Figure 2B ).
Secreted protein and heat-killed probiotic strains selectively modulate macrophage subset NFκB activity
Both TNFα and IL-6 are regulated by NFκB and exhibit binding consensus sequences in their respective promoter regions. Any such regulation of the expression of these inflammatory cytokines by probiotic bacteria was expected to be as a consequence of modulation of NFκB activity. When comparing profiles between TNFα, IL-6 and NFκB, these data are suggestive that probiotic regulation of these pro-inflammatory cytokines is largely independent of NFκB activity. One clear observation was that the probiotic secreted protein augmented NFκB activation in CD14 lo M1, CD14 lo M2 and CD14 hi M2 macrophages. SP only partially or failed to suppress NFκB activity upon LPS stimulation of CD14 hi M1s ( Figure 3B ). SP augmented NFκB in CD14 lo M1s (LPS control level of 0.530±0.063 arbitrary units) by 53%, 32%, 69%, 47% and 60% ( Figure 3A) ; CD14 lo M2s (LPS control 0.427±0.009 arbitrary units) by 92%, 116%, 63%, 83% and 156% ( Figure 3C ) and CD14 hi M2s (LPS control 0.363±0.005 arbitrary units) by 36%, 97%, 138%, 58% and 144% for BB, LR, LF, LS and LP secreted protein extracts, respectively ( Figure 3D ). With the exception of LF-SP, where no modulation of NFκB was observed, the probiotic SPs only partially suppressed CD14 hi M1 NFκB (LPS control 1.198±0.084 arbitrary units) by 13%, 23%, 30% and 20% for BB, LR, LS and LP, respectively ( Figure 3B ). The heat-killed preparations seemed to partially suppress M1 NFκB activation whereas they augmented NFκB activation in the M2 macrophage subset. In both CD14 lo M1 and CD14 hi M1s, HK-BB failed to modulate NFκB activity. The HK-LABs suppressed NFΚB: where in CD14 lo M1s, LPS-induced NFκB activity was suppressed by 42%, 25%, 28% and 31% ( Figure 3A ) and in CD14 hi M1s by 28%, 32%, 96% and 28% for LR, LF, LS and LP, respectively ( Figure 3B ). HK-LABs generally augmented LPS-induced NFκB activity in M2 macrophages, whereas the heat-killed preparation of B. breve failed to modulate NFκB activity. HK-probiotics augmented NFκB activity in CD14 hi M2s by 29%, 65%, 125% and 59% for LR, LF, LS and LP, respectively ( Figure 3D ). Finally, in the case of CD14 lo M2s, HKs from LF, LS and LP weakly modulated NFκB activity, augmenting by 26%, 20% and 33%, respectively ( Figure 3C ).
Discussion and conclusions
The probiotic bacterial stains (BB, LR, LF, LS and LP) differentially modulate macrophage production of the inflammatory mediator cytokines TNFα and IL-6. Immunomodulation of such macrophage-derived mediators is dependent on macrophage subset present in the mucosa, the CD14 expression and the format by which the probiotic is presented, i.e. bacterial cell wall associated (contact signal) or soluble secreted product (non contact-mediated signal).
Probiotic bacteria used in this study exhibited a strong proinflammatory effect on CD14 hi M1 macrophages which mimic infiltrating, inflammatory mucosal macrophages. Both heat-killed (HK)-and secreted protein (SP)-preparations augmented LPS-induced TNFα production in these macrophages. In general, CD14 lo M1 macrophage TNFα was partially suppressed by these probiotic preparations with the exception of HK-LR, BB-SP and LS-SP which failed to modulate TNFα. These contrasting data between CD14 hi and CD14 lo M1s highlight an important role for CD14 expression in probiotic immunomodulation. M2 macrophages were relatively poor producers of TNFα. CD14 lo M2 cells however, which mimic homeostatic mucosal macrophages, show a partial probiotic modulation; all HK-strains suppressed LPSinduced TNFα, most SPs were suppressive apart from LR-SP which up-regulated TNFα. With respect to CD14 hi M2 macrophage TNFα production, heat-killed LABs augmented LPS-induced TNFα whereas B. breve failed to modulate this cytokine. This modulatory activity would appear to be associated with the bacterial cell, as secreted protein failed to modulate pro-inflammatory TNFα in CD14 hi M2 cells. IL-6 production was differentially modulated by HK and SP probiotic preparations. HK-LF, HK-LS and HK-LP suppressed CD14 hi M1 macrophage IL-6 whereas the secreted protein from these three probiotics augmented IL-6. BB and LR failed to modulate this cytokine. CD14 lo M1 macrophages produce a higher level of IL-6 compared to the CD14 hi M1s. They also exhibit differential regulation by probiotics, in contrast to observations of modulation of CD14 hi M1s; HK-LR, HK-LS and HK-LP augmented IL-6. M2 macrophages produce higher levels of IL-6 than M1s and both CD14 hi and CD14 lo M2 macrophage IL-6 production was suppressed by both HK-and SP-probiotics used in this study. CD14 hi M2 macrophages were extremely sensitive to probiotic suppression of LPS-induced IL-6. For the first time in this study, B. breve demonstrated a clear immunoregulatory capacity, where both SP and HK extracts suppressed IL-6 in both CD14 hi and CD14 lo M2s. Thus, probiotics differentially modulate the pro-inflammatory cytokines TNFα and IL-6 produced by LPS-stimulated M1 and M2 macrophages.
LPS induction of monocyte/macrophage pro-inflammatory cytokine expression is well established to be NFκB -regulated (Bondeson et al., 1999) . Indeed, both IL-6 and TNFα are regulated by NFκB and express NFκB binding consensus sequences in their promoter regions. It was expected that NFκB activation would parallel probiotic regulation of TNFα and IL-6. In fact, the only profile that partially parallels NFκB activation is the regulation of IL-6 production by CD14 hi M1s. M2 macrophage NFκB activation is partially augmented by these probiotic bacteria. Regulation of IL-6 however, resulted in the opposite effect, suppression, suggesting that probiotic modulation of IL-6 was NFκB -independent. In addition, probiotic augmentation of TNFα by pro-inflammatory CD14 hi M1 macrophages was also NFκB -independent, as NFκB was either partially suppressed or unaltered. Modulation of CD14 hi M2 TNFα did, however, parallel that of NFκB activation. Due to this poor level of association of NFκB with cytokine production, it is likely that other signalling pathways are involved in probiotic regulation. LPS activates mitogen activated protein kinases (MAPKs) (Foey et al., 1998) . These pathways are regulated by the probiotic bacterium Lactobacillus reuteri which suppressed macrophage TNFα production through the inhibition of the transcription factor, AP-1 (Lin et al., 2008) . AP-1 inhibition is suggestive that this probiotic may effect its regulation by suppression of the p38, p42/p44 ERK and JNK MAPKs. In addition to probiotics modulating MAPKs, cytokine production may be modulated directly via activation of other signal regulators or indirectly through the downstream activity of early-expressed cytokines.
Probiotics are generally Gram-positive bacteria that express peptidoglycan in their cell wall. Peptidoglycan is recognised by the intracellular receptor NOD2 (Hasegawa et al., 2006) , which, through expression of short and long splice variants can positively or negatively regulate NFκB/ MAPK-dependent pro-inflammatory cytokines (Girardin et al., 2003; Rosentiel et al., 2006) . Peptidoglycan also activates the transcription factors AP-1 and CREB/ATF in M2-like macrophages (Gupta et al., 1999) . Several pro-inflammatory cytokine promotors possess CREB/ATF-binding sequences, indeed cAMP/CREB negatively regulates the proinflammatory cytokine TNFα, whilst, at the same time, inducing the expression of the anti-inflammatory cytokine IL-10 (Foey et al., 2003) . Thus, pro-inflammatory cytokines may be modulated indirectly by probiotic bacteria through the production of anti-inflammatory/regulatory cytokines. IL-10 may induce suppressor of cytokine signalling (SOCS) proteins, suppressing the activity and expression of several cytokines. One such example includes IFNγ, significant for activation and differentiation of pro-inflammatory M1 macrophages. Interestingly, similar to IL-10 regulation, IL-6, when acting as an anti-inflammatory mediator, induces SOCS (Xing et al., 1998) . This negative feedback mechanism may partially explain the differing probiotic regulation observed between IL-6 and TNFα production, in particular, for CD14 hi M1 and M2 macrophages. Additionally, there is a reciprocal relationship between IL-6 and TNFα, in conditions where TNFα is augmented or highly expressed, IL-6 expression is low/suppressed. These regulatory processes suggest probiotic bacteria to modulate macrophage-driven responses by inducing endotoxin tolerance to PAMPs. In this study, tolerance may be initiated via chronic LPS stimulation or cross-tolerisation through NOD2, TLR2, TNF-R and IL-1βR signalling (Ferlito et al., 2001; and reviewed in Biswas and Lopez-Collazo, 2009 ). This study suggests that regulation/tolerisation is likely to be dependent on environmental stimuli, macrophage lineage and CD14 expression. Future research will focus on the mechanisms of endotoxin tolerance, mediated by probiotics, facilitating a comprehensive mechanistic understanding of probiotic immunomodulatory function.
With respect to CD14 expression, CD14 hi expression levels dramatically affected LPS-induced TNFα production, where the probiotic bacteria used generally augmented this proinflammatory cytokine in both M1 and M2 macrophages; modulation was less pronounced in CD14 lo macrophages. CD14 has been described to be both pro-inflammatory, through oligomerisation with the LPS receptor TLR4, and anti-inflammatory through its action as a scavenger receptor for apoptotic cells. The relative suppression of TNFα produced by CD14 lo macrophages would suggest that modulation is as a consequence of down-regulation of the CD14/TLR4/TLR2 pro-inflammatory complex rather than downstream suppressive function of IL-10 or TGFβ induced by the recognition and phagocytosis of apoptotic cells.
M2 IL-6 production was suppressed by probiotics with a stronger suppression evident in CD14 hi M2s. Regarding the fact that IL-6 is both pro-and anti-inflammatory, probiotic suppression of this cytokine may exhibit inflammatory and tolerogenic/suppressive function. Modulation of M1 IL-6 production was less clear and exhibited both suppressive and augmentation responses for both CD14 hi and CD14 lo which appeared to be strain selective and dependent on form of probiotic used to modulate the macrophage response.
Generally, the form of probiotic used (heat-killed or secreted protein) showed little difference in modulation of LPS-induced TNFα and IL-6. Two notable exceptions presented themselves for CD14 hi M2 TNFα and CD14 hi M1 IL-6 production: heat-killed LABs strongly augmented CD14 hi M2 TNFα whereas secreted protein weakly modulated this cytokine. On the other hand, CD14 hi M1 IL-6 was suppressed by HK-preparations of L. fermentum, L. salivarius and L. plantarum whereas their secreted proteins partially augmented IL-6. Heat-killed probiotics utilised, investigated the immunomodulatory capability of cell-associated factors whereas secretory protein preparation investigated the potential for secreted, soluble immunomodulators. Preliminary SDS-PAGE analysis has identified several proteins either consistent between probiotic strains or strain-specific (data not shown). A previous investigation on L. rhamnosus GG conditioned medium identified several potential immunoregulators including a cell-wall-associated hydrolase, sepin B1 and a transcriptional regulator (Sanchez et al., 2009) . Additionally, secreted immunomodulatory proteins have been suggested to modulate signalling pathways driving pro-inflammatory cytokine production and function (Frick et al., 2007; Yan et al., 2007) . From this and other studies it can be concluded that beneficial immunomodulatory effects are associated with both bacterial cell-associated and secretable fractions, thus any future modulation of the immune system is best considering this, making use of both fractions provided by delivery of live probiotic strains either individually or in combination.
Cytokine production acts as a useful readout for probiotic immunomodulation. These bacteria are capable of both driving immune responses towards predominant Th 1 and Th 2 responses and suppressing such responses. This suggests probiotics to manipulate and redress immunopathological mechanisms: Th 1 -driven pathologies such as CD, may benefit from probiotics that either suppress harmful immune reactions or induce type II cytokines (IL-10, IL-4, IL-13) and conversely, Th 2 -driven pathologies such as ulcerative colitis, may benefit from immunosuppressive probiotics or those that induce type I cytokine expression (IFNγ, IL-12 and TNFα). Combinations of probiotics will allow development of disease-groupspecific treatments (Th 1 or Th 2 -driven) based on a thorough understanding of the immunopathogenic mechanisms. In the context of mucosal macrophages, some probiotics may be inappropriate in inflammatory pathologies where CD14 hi M1 subset cells predominate (Zareie et al., 2001) as, according to findings in this study, probiotic treatment may enhance inflammation by augmentation of TNFα production. A cautionary approach to their usage is recommended. On the other hand, probiotic treatment of CD14 lo M2s, resembling homeostatic/regulatory mucosal macrophages (Platt and Mowat, 2008; Smith et al., 2001; Smythies et al., 2005) , fails to augment inflammatory cytokines and may well induce expression of the regulatory cytokines, IL-10 and TGFβ, resulting in tolerance/immune hyporesponsiveness.
In conclusion, probiotic modulation of macrophage inflammatory cytokines TNFα and IL-6 is largely NFκB-independent, but dependent on macrophage subset and the nature by which the probiotic is introduced. Probiotic strains used can differentially exert both immune activatory or suppressive functions. Future probiotic development will consider whether they are to be used prophylactically in healthy individuals or as a therapeutic treatment of defined pathological conditions, probiotic strain-specific effects, gut mucosal integrity and immune phenotype of mucosal macrophages -one step closer to personalised medicine!
